Vera Therapeutics Inc - Ordinary Shares - Class A Aktie News

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtual...

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p

BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A c...

Vera Therapeutics, Inc. ( VERA ) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy November 6, 2025 4:30 PM EST Company Participants Marshall Fordyce - Founder, President, CEO & Director Matt Skelton - Executive Vice President of Commercial Robert Brenner - Chief Medical Officer Conference Call Participants Richard Lafayette Anupam Rama - JPMorgan Chase & Co, Re...

BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN) were presented as a featured late-breaking oral presentation during the opening plenary session of the American Society of Nephrology (ASN) Kidney Week 2025 and simultaneously published in The New England Journal of ...

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. com...

BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an investor call and webcast at 4:30 PM ET on Thursday, November 6, 2025 to review the data from the ORIGIN P...

BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be delivered as ...